- Home
- ESPR vs TALK Comparison
ESPR vs TALK Comparison
Compare ESPR & TALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- TALK
- Stock Information
- Founded
- ESPR 2008
- TALK 2012
- Country
- ESPR United States
- TALK United States
- Employees
- ESPR N/A
- TALK N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- TALK Medical/Nursing Services
- Sector
- ESPR Health Care
- TALK Health Care
- Exchange
- ESPR Nasdaq
- TALK Nasdaq
- Market Cap
- ESPR 534.3M
- TALK 442.1M
- IPO Year
- ESPR 2013
- TALK N/A
- Fundamental
- Price
- ESPR $2.55
- TALK $2.85
- Analyst Decision
- ESPR Buy
- TALK Buy
- Analyst Count
- ESPR 6
- TALK 6
- Target Price
- ESPR $6.50
- TALK $4.50
- AVG Volume (30 Days)
- ESPR 7.0M
- TALK 1.0M
- Earning Date
- ESPR 11-06-2025
- TALK 10-28-2025
- Dividend Yield
- ESPR N/A
- TALK N/A
- EPS Growth
- ESPR N/A
- TALK N/A
- EPS
- ESPR N/A
- TALK 0.02
- Revenue
- ESPR $268,125,000.00
- TALK $202,611,000.00
- Revenue This Year
- ESPR $13.05
- TALK $22.35
- Revenue Next Year
- ESPR N/A
- TALK $21.66
- P/E Ratio
- ESPR N/A
- TALK $166.40
- Revenue Growth
- ESPR N/A
- TALK 17.43
- 52 Week Low
- ESPR $0.69
- TALK $2.22
- 52 Week High
- ESPR $3.94
- TALK $4.36
- Technical
- Relative Strength Index (RSI)
- ESPR 47.71
- TALK 58.60
- Support Level
- ESPR $2.35
- TALK $2.72
- Resistance Level
- ESPR $3.41
- TALK $2.86
- Average True Range (ATR)
- ESPR 0.18
- TALK 0.11
- MACD
- ESPR -0.03
- TALK 0.02
- Stochastic Oscillator
- ESPR 9.79
- TALK 70.27
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About TALK Talkspace Inc.
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.